Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma
Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.
New Subcutaneous Daratumumab Formulation Overcomes Infusion Barrier for Patients
Daratumumab-based regimens have shown efficacy across all lines of therapy in multiple myeloma (MM), but the agent requires a long intravenous infusion time, lasting...
Iberdomide: A New Immunomodulatory Drug for Heavily Refractory Myeloma
One-third of patients with relapsed/refractory multiple myeloma (MM) responded to treatment with the investigational agent iberdomide, according to early results from a first-in-human trial. Sagar...
AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma
In updated results from the first-in-human study of the bispecific T-cell engager (BITE) AMG 420, the agent continued to demonstrate clinical activity in patients...
Isatuximab Combo Improves Progression-Free Survival in Pretreated Myeloma
In an update from the phase III ICARIA-MM trial, researchers reported that the combination of the anti-CD38 monoclonal antibody isatuximab with pomalidomide and dexamethasone...
Hematologic Malignancies Drive In-Hospital Death Rates
In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...
In Myeloma, New Drugs, Skyrocketing Price Tags
In late February, seven pharmaceutical executives were called before the U.S. Senate Finance Committee to testify about the prices of brand-name prescription drugs, which...
FDA Halts Trials of Venetoclax for Myeloma
The U.S. Food and Drug Administration (FDA) has issued a warning to health-care professionals and clinical investigators about the risks associated with the investigational...
FDA’s ODAC Rejects Selinexor for Myeloma
In an 8-to-5 vote, the U.S. Food and Drug Administration's (FDA’s) Oncologic Drug Advisory Committee (ODAC) decided against recommending accelerated approval of selinexor for...
Post-Transplant Ixazomib Maintenance Prolongs Survival in Newly Diagnosed Myeloma
For patients with newly diagnosed multiple myeloma (MM) who relapse following autologous hematopoietic cell transplantation (AHCT), maintenance therapy with the oral proteasome inhibitor (PI)...
Current Issue
June 2019, Volume 5, Issue 7
This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.
